首页|阿莫西林克拉维酸钾干混悬剂在中国成年健康受试者的药代动力学研究

阿莫西林克拉维酸钾干混悬剂在中国成年健康受试者的药代动力学研究

扫码查看
目的 观察阿莫西林克拉维酸钾干混悬剂(阿莫西林400 mg与克拉维酸57 mg/5 mL)于空腹及餐后状态下在中国健康受试者中的药代动力学(PK)特征.方法 空腹试验与餐后试验各自入组36例中国健康成年受试者,本研究用单剂量、随机、开放性、两周期实验方案设计,每个周期中口服以水配制而成的受试制剂(或参比制剂)阿莫西林克拉维酸钾干混悬剂10 mL,采集静脉血样,用液相色谱-串联质谱法测定人血浆中阿莫西林与克拉维酸钾的血药浓度,用Phoe-nixWinNonlin8.2软件非房室模型分析方法对血浆中2种有效成分的PK参数进行分析.结果 空腹组阿莫西林的AUC0-∞为(36.81±5.16)μg·mL-1·h,AUC0-t为(36.51±5.10)μg·mL-1·h,Cmax 为(13.76±3.13)μ.g.mL-1,t1/2 为(1.42±0.16)h,tmax为 1.25 h;餐后组阿莫西林的 AUC0-∞为(39.65±5.86)µg·mL-1·h,AUC0-t 为(37.43±5.70)μg·mL-1·h,Cmax 为(8.57±1.70)µg·mL-1,t1/2为(1.77±0.57)h,tmax为 3.25 h.空腹组克拉维酸的 AUC0-∞为(5.01±2.05)μg·mL-1-h,AUC0-t为(4.973±2.05)µg·mL-1·h,Cmax为(2.05±0.87)μg·mL-1,t1/2为(1.20±0.11)h,tmax为 1.25 h;餐后组克拉维酸的 AUC0-∞为(2.54±1.37)μg·mL-1·h,AUC0-t为(2.50±1.36)μg·mL-1·h,Cmax为(0.76±0.40)μ.g-mL-1,t1/2为(1.13±0.16)h,tmax为 2.50 h.结论 高脂高热量饮食后服药会显著降低克拉维酸的吸收速度及吸收程度,对阿莫西林的吸收及代谢无较大影响.
Pharmacokinetic study of amoxicillin potassium clavulanate dry suspension in adult healthy Chinese subjects
Objective To observe the pharmacokinetic profile of amoxicillin potassium clavulanate dry suspension(amoxicillin 400 mg with clavulanate 57 mg/5 mL)in fasting and fed states in healthy Chinese subjects.Methods Thirty-six healthy Chinese adult subjects were enrolled in each of the fasting and postprandial trials.A single-dose,randomized,open-ended,two-cycle experimental protocol was used in both groups,in which 10 mL of the test preparation(or the reference preparation),amoxicillin potassium clavulanate,was administered orally with water in each cycle,and venous blood samples were collected for the determination of amoxicillin in human plasma using liquid chromatography-tandem mass spectrometry.The blood concentrations of amoxicillin and potassium clavulanate in human plasma were determined by liquid chromatography-tandem mass spectrometry(LC-MS/MS),and the pharmacokinetic(PK)parameters of the two active ingredients in the plasma were analyzed by the non-atrial modeling method using PhoenixWinNonlin 8.2 software.Results The pharmacokinetic parameters of the two main active ingredients were as follows:AUC0_∞ of amoxicillin in the fasting group was(36.81±5.16)μg·mL-1·h;AUC0_twas(36.51±5.10)μg·mL-1·h;Cmax was(13.76±3.13)μg·mL-1;t1/2 was(1.42±0.16)h;tmax was 1.25 h.AUC0-∞ for amoxicillin in the postprandial group was(39.65±5.86)μg·mL-1·h;AUC0-t was(37.43±5.70)μg·mL-1·h;Cmaxwas(8.57±1.70)μg·mL-1,t1/2 was(1.77±0.57)h;tmax was 3.25 h.AUC0-∞ of clavulanic acid in fasting group was(2.54±1.37)μg·mL-1·h;AUC0_t was(4.97±2.05)μg·mL-1·h;Cmax was(2.05±0.87)μg·mL-1;t1/2 was(1.20±0.11)h,tmax was 1.25 h.In the postprandial group clavulanic acid had an AUC0-∞ of(2.54±1.37)μg·mL-1·h;AUC0-twas(2.50±1.36)μg·mL-1·h;Cmaxwas(0.76±0.40)μg·mL-1;t1/2 was(1.13±0.16)h;tmax was 2.50 h.Conclusion Taking the drug after a high-fat,high-calorie diet significantly reduced the rate and extent of clavulanic acid absorption,and had no major effect on the absorption and metabolism of amoxicillin.

amoxicillinclavulanic acidpharmacokineticsliquid chromatography-tandem mass spectrometryhealthy Chinese subjects

袁福淼、潘芸芸、许重远

展开 >

南方医科大学南方医院临床药学中心,广东 广州 510512

阿莫西林 克拉维酸 药代动力学 液相色谱-串联质谱 中国健康受试者

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(22)